Why Did Bill Ackman Buy Alphabet Stock?
Bill Ackman has become famous in the investing world for…
Buy
67
BUGDF Quote, Financials, Valuation and Earnings
Last price:
$7.91
Seasonality move
:
0.79%
Day range:
$7.91 - $7.91
52-week range:
$6.40 - $7.91
Dividend yield:
1.86%
P/E ratio:
31.81x
P/S ratio:
9.44x
P/B ratio:
7.32x
Volume:
--
Avg. volume:
--
1-year change:
22.88%
Market cap:
$6.3B
Revenue:
$729.3M
EPS (TTM):
$0.25
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BUGDF
Bumrungrad Hospital PCL
|
-- | -- | -- | -- | -- |
|
BDUUF
Bangkok Dusit Medical Services PCL
|
-- | -- | -- | -- | -- |
|
CVM
CEL-SCI
|
-- | -- | -- | -- | $8.00 |
|
IGC
IGC Pharma
|
$305K | -$0.02 | 3.39% | -50% | $3.88 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.24 | 14.03% | -95.43% | $0.85 |
|
NIVF
NewGenIvf Group
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BUGDF
Bumrungrad Hospital PCL
|
$7.91 | -- | $6.3B | 31.81x | $0.09 | 1.86% | 9.44x |
|
BDUUF
Bangkok Dusit Medical Services PCL
|
$0.66 | -- | $10.5B | 22.90x | $0.01 | 3.37% | 3.42x |
|
CVM
CEL-SCI
|
$0.29 | $8.00 | $22.4M | -- | $0.00 | 0% | -- |
|
IGC
IGC Pharma
|
$0.30 | $3.88 | $23.8M | -- | $0.00 | 0% | 17.59x |
|
NBY
NovaBay Pharmaceuticals
|
$0.58 | $0.85 | $3.4M | -- | $0.00 | 0% | 0.16x |
|
NIVF
NewGenIvf Group
|
$0.35 | -- | $2.6M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BUGDF
Bumrungrad Hospital PCL
|
0.08% | -0.086 | 0.01% | 4.73x |
|
BDUUF
Bangkok Dusit Medical Services PCL
|
9.5% | 0.255 | 2.47% | 0.94x |
|
CVM
CEL-SCI
|
-- | 1.752 | -- | -- |
|
IGC
IGC Pharma
|
2.1% | -1.475 | 0.51% | 0.21x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | 0.451 | 1.51% | 0.75x |
|
NIVF
NewGenIvf Group
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BUGDF
Bumrungrad Hospital PCL
|
$91.3M | $61.4M | 27.69% | 27.72% | 34.95% | $50.9M |
|
BDUUF
Bangkok Dusit Medical Services PCL
|
$304.7M | $156.2M | 14.33% | 15.75% | 19.66% | $11.1M |
|
CVM
CEL-SCI
|
-- | -$6.9M | -- | -- | -- | -$4.2M |
|
IGC
IGC Pharma
|
$104K | -$1.9M | -114.2% | -116.24% | -730.74% | -$1.4M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
NIVF
NewGenIvf Group
|
-- | -- | -- | -- | -- | -- |
Bumrungrad Hospital PCL vs. Competitors
-
Which has Higher Returns BUGDF or BDUUF?
Bangkok Dusit Medical Services PCL has a net margin of 28.23% compared to Bumrungrad Hospital PCL's net margin of 15.81%. Bumrungrad Hospital PCL's return on equity of 27.72% beat Bangkok Dusit Medical Services PCL's return on equity of 15.75%.
Company Gross Margin Earnings Per Share Invested Capital BUGDFBumrungrad Hospital PCL50.5% $0.06 $869.7M BDUUFBangkok Dusit Medical Services PCL37.83% $0.01 $3.3B -
What do Analysts Say About BUGDF or BDUUF?
Bumrungrad Hospital PCL has a consensus price target of --, signalling downside risk potential of --. On the other hand Bangkok Dusit Medical Services PCL has an analysts' consensus of -- which suggests that it could fall by --. Given that Bumrungrad Hospital PCL has higher upside potential than Bangkok Dusit Medical Services PCL, analysts believe Bumrungrad Hospital PCL is more attractive than Bangkok Dusit Medical Services PCL.
Company Buy Ratings Hold Ratings Sell Ratings BUGDFBumrungrad Hospital PCL0 0 0 BDUUFBangkok Dusit Medical Services PCL0 0 0 -
Is BUGDF or BDUUF More Risky?
Bumrungrad Hospital PCL has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bangkok Dusit Medical Services PCL has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.674%.
-
Which is a Better Dividend Stock BUGDF or BDUUF?
Bumrungrad Hospital PCL has a quarterly dividend of $0.09 per share corresponding to a yield of 1.86%. Bangkok Dusit Medical Services PCL offers a yield of 3.37% to investors and pays a quarterly dividend of $0.01 per share. Bumrungrad Hospital PCL pays 52.75% of its earnings as a dividend. Bangkok Dusit Medical Services PCL pays out 69.55% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BUGDF or BDUUF?
Bumrungrad Hospital PCL quarterly revenues are $180.8M, which are smaller than Bangkok Dusit Medical Services PCL quarterly revenues of $805.5M. Bumrungrad Hospital PCL's net income of $51M is lower than Bangkok Dusit Medical Services PCL's net income of $127.4M. Notably, Bumrungrad Hospital PCL's price-to-earnings ratio is 31.81x while Bangkok Dusit Medical Services PCL's PE ratio is 22.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bumrungrad Hospital PCL is 9.44x versus 3.42x for Bangkok Dusit Medical Services PCL. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BUGDFBumrungrad Hospital PCL9.44x 31.81x $180.8M $51M BDUUFBangkok Dusit Medical Services PCL3.42x 22.90x $805.5M $127.4M
-
Which has Higher Returns BUGDF or CVM?
CEL-SCI has a net margin of 28.23% compared to Bumrungrad Hospital PCL's net margin of --. Bumrungrad Hospital PCL's return on equity of 27.72% beat CEL-SCI's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BUGDFBumrungrad Hospital PCL50.5% $0.06 $869.7M CVMCEL-SCI-- -$0.11 -- -
What do Analysts Say About BUGDF or CVM?
Bumrungrad Hospital PCL has a consensus price target of --, signalling downside risk potential of --. On the other hand CEL-SCI has an analysts' consensus of $8.00 which suggests that it could grow by 2654.82%. Given that CEL-SCI has higher upside potential than Bumrungrad Hospital PCL, analysts believe CEL-SCI is more attractive than Bumrungrad Hospital PCL.
Company Buy Ratings Hold Ratings Sell Ratings BUGDFBumrungrad Hospital PCL0 0 0 CVMCEL-SCI1 0 0 -
Is BUGDF or CVM More Risky?
Bumrungrad Hospital PCL has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.951, suggesting its less volatile than the S&P 500 by 4.939%.
-
Which is a Better Dividend Stock BUGDF or CVM?
Bumrungrad Hospital PCL has a quarterly dividend of $0.09 per share corresponding to a yield of 1.86%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bumrungrad Hospital PCL pays 52.75% of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend. Bumrungrad Hospital PCL's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BUGDF or CVM?
Bumrungrad Hospital PCL quarterly revenues are $180.8M, which are larger than CEL-SCI quarterly revenues of --. Bumrungrad Hospital PCL's net income of $51M is higher than CEL-SCI's net income of -$7.1M. Notably, Bumrungrad Hospital PCL's price-to-earnings ratio is 31.81x while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bumrungrad Hospital PCL is 9.44x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BUGDFBumrungrad Hospital PCL9.44x 31.81x $180.8M $51M CVMCEL-SCI-- -- -- -$7.1M
-
Which has Higher Returns BUGDF or IGC?
IGC Pharma has a net margin of 28.23% compared to Bumrungrad Hospital PCL's net margin of -711.67%. Bumrungrad Hospital PCL's return on equity of 27.72% beat IGC Pharma's return on equity of -116.24%.
Company Gross Margin Earnings Per Share Invested Capital BUGDFBumrungrad Hospital PCL50.5% $0.06 $869.7M IGCIGC Pharma40.47% -$0.02 $6.4M -
What do Analysts Say About BUGDF or IGC?
Bumrungrad Hospital PCL has a consensus price target of --, signalling downside risk potential of --. On the other hand IGC Pharma has an analysts' consensus of $3.88 which suggests that it could grow by 1195.55%. Given that IGC Pharma has higher upside potential than Bumrungrad Hospital PCL, analysts believe IGC Pharma is more attractive than Bumrungrad Hospital PCL.
Company Buy Ratings Hold Ratings Sell Ratings BUGDFBumrungrad Hospital PCL0 0 0 IGCIGC Pharma2 0 0 -
Is BUGDF or IGC More Risky?
Bumrungrad Hospital PCL has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.449, suggesting its more volatile than the S&P 500 by 44.948%.
-
Which is a Better Dividend Stock BUGDF or IGC?
Bumrungrad Hospital PCL has a quarterly dividend of $0.09 per share corresponding to a yield of 1.86%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bumrungrad Hospital PCL pays 52.75% of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend. Bumrungrad Hospital PCL's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BUGDF or IGC?
Bumrungrad Hospital PCL quarterly revenues are $180.8M, which are larger than IGC Pharma quarterly revenues of $257K. Bumrungrad Hospital PCL's net income of $51M is higher than IGC Pharma's net income of -$1.8M. Notably, Bumrungrad Hospital PCL's price-to-earnings ratio is 31.81x while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bumrungrad Hospital PCL is 9.44x versus 17.59x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BUGDFBumrungrad Hospital PCL9.44x 31.81x $180.8M $51M IGCIGC Pharma17.59x -- $257K -$1.8M
-
Which has Higher Returns BUGDF or NBY?
NovaBay Pharmaceuticals has a net margin of 28.23% compared to Bumrungrad Hospital PCL's net margin of -49.65%. Bumrungrad Hospital PCL's return on equity of 27.72% beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital BUGDFBumrungrad Hospital PCL50.5% $0.06 $869.7M NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About BUGDF or NBY?
Bumrungrad Hospital PCL has a consensus price target of --, signalling downside risk potential of --. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 46.55%. Given that NovaBay Pharmaceuticals has higher upside potential than Bumrungrad Hospital PCL, analysts believe NovaBay Pharmaceuticals is more attractive than Bumrungrad Hospital PCL.
Company Buy Ratings Hold Ratings Sell Ratings BUGDFBumrungrad Hospital PCL0 0 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is BUGDF or NBY More Risky?
Bumrungrad Hospital PCL has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.
-
Which is a Better Dividend Stock BUGDF or NBY?
Bumrungrad Hospital PCL has a quarterly dividend of $0.09 per share corresponding to a yield of 1.86%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bumrungrad Hospital PCL pays 52.75% of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend. Bumrungrad Hospital PCL's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BUGDF or NBY?
Bumrungrad Hospital PCL quarterly revenues are $180.8M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Bumrungrad Hospital PCL's net income of $51M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Bumrungrad Hospital PCL's price-to-earnings ratio is 31.81x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bumrungrad Hospital PCL is 9.44x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BUGDFBumrungrad Hospital PCL9.44x 31.81x $180.8M $51M NBYNovaBay Pharmaceuticals0.16x -- $2.4M -$1.2M
-
Which has Higher Returns BUGDF or NIVF?
NewGenIvf Group has a net margin of 28.23% compared to Bumrungrad Hospital PCL's net margin of --. Bumrungrad Hospital PCL's return on equity of 27.72% beat NewGenIvf Group's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BUGDFBumrungrad Hospital PCL50.5% $0.06 $869.7M NIVFNewGenIvf Group-- -- -- -
What do Analysts Say About BUGDF or NIVF?
Bumrungrad Hospital PCL has a consensus price target of --, signalling downside risk potential of --. On the other hand NewGenIvf Group has an analysts' consensus of -- which suggests that it could fall by --. Given that Bumrungrad Hospital PCL has higher upside potential than NewGenIvf Group, analysts believe Bumrungrad Hospital PCL is more attractive than NewGenIvf Group.
Company Buy Ratings Hold Ratings Sell Ratings BUGDFBumrungrad Hospital PCL0 0 0 NIVFNewGenIvf Group0 0 0 -
Is BUGDF or NIVF More Risky?
Bumrungrad Hospital PCL has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NewGenIvf Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BUGDF or NIVF?
Bumrungrad Hospital PCL has a quarterly dividend of $0.09 per share corresponding to a yield of 1.86%. NewGenIvf Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bumrungrad Hospital PCL pays 52.75% of its earnings as a dividend. NewGenIvf Group pays out -- of its earnings as a dividend. Bumrungrad Hospital PCL's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BUGDF or NIVF?
Bumrungrad Hospital PCL quarterly revenues are $180.8M, which are larger than NewGenIvf Group quarterly revenues of --. Bumrungrad Hospital PCL's net income of $51M is higher than NewGenIvf Group's net income of --. Notably, Bumrungrad Hospital PCL's price-to-earnings ratio is 31.81x while NewGenIvf Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bumrungrad Hospital PCL is 9.44x versus -- for NewGenIvf Group. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BUGDFBumrungrad Hospital PCL9.44x 31.81x $180.8M $51M NIVFNewGenIvf Group-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Bill Ackman Buy Brookfield Stock?
Bill Ackman of Pershing Square Capital has made a number…
Why Is Chewy Stock Up — And Will It Keep Climbing?
We are all witnesses to the crazy e-commerce industry boom…
Stock Ideas
Buy
61
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Sell
27
SAIA alert for Apr 26
Saia [SAIA] is down 30.77% over the past day.
Sell
48
APPF alert for Apr 26
AppFolio [APPF] is down 18.16% over the past day.
Sell
15
KNSL alert for Apr 26
Kinsale Capital Group [KNSL] is down 16.33% over the past day.
